Guru Ownership Trend
Guru Analysis for Halozyme Therapeutics, Inc. (HALO)
Halozyme Therapeutics, Inc. (HALO), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 8 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $293.43 M.
Top institutional holders include Cliff Asness and Joel Greenblatt.
Institutional sentiment is currently Bullish. This is evidenced by a $3.29 M net inflow during the quarter.
Recent activity highlights Joel Greenblatt who increased their stake by 69.9%. Conversely, Cliff Asness reduced exposure by 12.3%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Halozyme Therapeutics, Inc. (HALO)
Major holders include Cliff Asness ($64.82 M), Joel Greenblatt ($48.27 M), Renaissance Technologies (RenTech) ($47.3 M). According to the latest reported data, 8 tracked investment managers collectively hold approximately 3.54 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $3.29 M, with 3 managers increasing positions and 6 managers reducing holdings.
During the most recent reporting period, 4 managers trimmed their positions, while 2 fully exited HALO. The total reported sell value was $27.81 M.
Yes, 0 managers opened new positions in HALO, and 3 increased their existing holdings. The total reported buy value was $31.11 M.
